Kidney international最新文献

{"title":"When two signals cross paths: cGAS-STING and ER stress in kidney disease progression","authors":"Ryo Yamada ,&nbsp;Motoko Yanagita","doi":"10.1016/j.kint.2024.11.023","DOIUrl":"10.1016/j.kint.2024.11.023","url":null,"abstract":"<div><div>Previous reports have suggested that both the endoplasmic reticulum (ER) stress and cyclic guanosine monophosphate–adenosine monophosphate synthase–stimulator of interferon genes pathways contribute to the progression of chronic kidney disease; however, the relationship between these 2 pathways in kidney injury has not been fully elucidated. Andrade-Silva <em>et al.</em> revealed that the cyclic guanosine monophosphate–adenosine monophosphate synthase–stimulator of interferon genes pathway can enhance ER stress through the protein kinase R-like ER kinase (PERK)–mediated signaling cascade in kidney tubular epithelial cells and sequentially augment fibrosis during kidney injury. Further studies are needed to elucidate the precise mechanisms by which the cyclic guanosine monophosphate–adenosine monophosphate synthase–stimulator of interferon genes pathway activates PERK-dependent ER stress in kidney tubular epithelial cells post injury.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 227-229"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","authors":"Vicente E. Torres ,&nbsp;Curie Ahn ,&nbsp;Thijs R.M. Barten ,&nbsp;Godela Brosnahan ,&nbsp;Melissa A. Cadnapaphornchai ,&nbsp;Arlene B. Chapman ,&nbsp;Emilie Cornec-Le Gall ,&nbsp;Joost P.H. Drenth ,&nbsp;Ron T. Gansevoort ,&nbsp;Peter C. Harris ,&nbsp;Tess Harris ,&nbsp;Shigeo Horie ,&nbsp;Max C. Liebau ,&nbsp;Michele Liew ,&nbsp;Andrew J. Mallett ,&nbsp;Changlin Mei ,&nbsp;Djalila Mekahli ,&nbsp;Dwight Odland ,&nbsp;Albert C.M. Ong ,&nbsp;Luiz F. Onuchic ,&nbsp;Olivier Devuyst","doi":"10.1016/j.kint.2024.07.010","DOIUrl":"10.1016/j.kint.2024.07.010","url":null,"abstract":"<div><div>The <em>Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease</em> (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations. The development of this guideline followed an explicit process of evidence review and appraisal, based on a rigorous, formal systematic literature review. The strength of recommendations follows the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points serving to direct clinical care or activities relating to areas for which a systematic review was not conducted. Limitations of the evidence are discussed. Research recommendations to address gaps in knowledge, and implications for policy and payment, are provided. The guideline targets a broad audience of healthcare providers, people living with ADPKD, and stakeholders involved in the various aspects of ADPKD care.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 234-254"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The authors reply","authors":"Yoshio Funahashi ,&nbsp;Seung Hun Park ,&nbsp;Jessica F. Hebert ,&nbsp;Mahaba B. Eiwaz ,&nbsp;Adam C. Munhall ,&nbsp;Tahnee Groat ,&nbsp;Lingxue Zeng ,&nbsp;Jonghan Kim ,&nbsp;Hak Soo Choi ,&nbsp;Michael P. Hutchens","doi":"10.1016/j.kint.2024.11.010","DOIUrl":"10.1016/j.kint.2024.11.010","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Page 361"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","authors":"","doi":"10.1016/j.kint.2024.07.009","DOIUrl":"10.1016/j.kint.2024.07.009","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages S1-S239"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PI3Kα in the pathogenesis and treatment of lupus nephritis","authors":"Vivek Kasinath ,&nbsp;George C. Tsokos","doi":"10.1016/j.kint.2024.11.004","DOIUrl":"10.1016/j.kint.2024.11.004","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 215-217"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in maturation and integration of kidney organoids for stem cell–based renal replacement therapy","authors":"Cathelijne W. van den Berg ,&nbsp;Sébastien J. Dumas ,&nbsp;Melissa H. Little ,&nbsp;Ton J. Rabelink","doi":"10.1016/j.kint.2024.10.028","DOIUrl":"10.1016/j.kint.2024.10.028","url":null,"abstract":"<div><div>Human pluripotent stem cell–derived kidney organoids hold promise for future applications in regenerative medicine. However, significant biological hurdles need to be overcome to enable their use as a transplantable stem cell–derived therapeutic graft. Current kidney organoid protocols do not recapitulate a complete integrated developing kidney, but embryonic kidney transplantations have provided clues for advancing maturation and functionality of kidney organoids. Transplantation, subsequent vascularization, and blood perfusion of kidney organoids improve nephron patterning and maturation, suggesting a role for angiocrine factors as well as metabolic wiring in these processes. Transplanted organoids exhibit filtration, but the resulting filtrate has no apparent exit path for excretion. Improved <em>in vitro</em> patterning of kidney organoids may be required such that a more structurally correct tissue is formed before transplant. Here we review current progress with transplantation of kidney organoids, as well as their engraftment and integration, and identify the key obstacles to therapeutic success and how these might be achieved.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 262-270"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The autoimmune architecture of childhood idiopathic nephrotic syndrome","authors":"Tho-Alfakar Al-Aubodah ,&nbsp;Ciriaco A. Piccirillo ,&nbsp;Howard Trachtman ,&nbsp;Tomoko Takano","doi":"10.1016/j.kint.2024.10.027","DOIUrl":"10.1016/j.kint.2024.10.027","url":null,"abstract":"<div><div>Idiopathic nephrotic syndrome, the most common glomerular disorder in children, has long been considered an immune-mediated disease based on the efficacy of glucocorticoids at inducing remission. Nevertheless, the immune processes leading to podocytopathy have largely remained elusive. The success of B-cell depletion with rituximab, descriptions of B-cell dysregulation during active disease, and the most recent discovery of autoantibodies targeting the major podocyte antigen nephrin point to an autoimmune humoral etiology for idiopathic nephrotic syndrome. Investigations of the immune factors involved in idiopathic nephrotic syndrome pathogenesis have uncovered common features with other autoimmune disorders that will aid in prognostication and in guiding the expansion of our glucocorticoid-sparing therapeutic arsenal. In this review, we discuss the emerging autoimmune architecture of idiopathic nephrotic syndrome, with a specific focus on pediatric steroid-sensitive disease, including the podocyte-reactive B-cell response that causes anti-podocyte antibodies, the predisposing genetic factors that shape the podocyte-reactive immune landscape, and the immune triggers driving active disease.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 271-279"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"journal club","authors":"","doi":"10.1016/j.kint.2024.11.024","DOIUrl":"10.1016/j.kint.2024.11.024","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 212-214"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143151879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients","authors":"Sophie Caillard ,&nbsp;Nicolas Meyer ,&nbsp;Morgane Solis ,&nbsp;Dominique Bertrand ,&nbsp;Maite Jaureguy ,&nbsp;Dany Anglicheau ,&nbsp;Laure Ecotiere ,&nbsp;Matthias Buchler ,&nbsp;Nicolas Bouvier ,&nbsp;Betoul Schvartz ,&nbsp;Jean Philippe Rerolle ,&nbsp;Anne Elisabeth Heng ,&nbsp;Lionel Couzi ,&nbsp;Agnes Duveau ,&nbsp;Emmanuel Morelon ,&nbsp;Yann LeMeur ,&nbsp;Léonard Golbin ,&nbsp;Eric Thervet ,&nbsp;Ilies Benotmane ,&nbsp;Samira Fafi-Kremer","doi":"10.1016/j.kint.2024.09.018","DOIUrl":"10.1016/j.kint.2024.09.018","url":null,"abstract":"<div><div>The MTOR inhibitors have demonstrated antiviral properties, and prior non-randomized studies have suggested they may have a suppressive effect on BKPyV replication. Here, in this randomized, multicenter, controlled trial (BKEVER study), we sought to evaluate the impact of everolimus (EVR) in facilitating the clearance of BKPyV compared to simply reducing immunosuppression among kidney transplant recipients (KTRs). All together, 130 KTRs presenting with BKPyV DNAemia were randomized 1:1 into two groups. The EVR group, in which mycophenolate mofetil (MMF) was replaced by EVR along with a decrease in calcineurin inhibitor trough levels and secondly the MMF group, in which the MMF dose was decreased by half along with a similar lowering of calcineurin inhibitor levels. The primary endpoint was the proportion of patients achieving viral clearance at six months. Secondary endpoints included the kinetics of BKPyV replication over time, the incidence of BKPyV-associated nephropathy, kidney graft function, the incidence of kidney graft rejection, and medication tolerability over two years. Significantly, BKPyV clearance was achieved in 55.7% of patients in the EVR group compared to 81.3% of patients in the MMF group at six months. The reduction in BKPyV DNA load was significantly more rapid in the MMF group. Calcineurin inhibitor trough levels were within expected target ranges and did not differ meaningfully between the two groups from randomization through month six. Two grafts were lost, and four patients died. Eleven patients in the EVR group and six patients in the MMF group developed biopsy-proven BKPyV nephropathy. Thus, in KTRs with BKPyV DNAemia, replacing MMF with EVR along with lowering calcineurin inhibitor levels did not lead to more frequent or faster clearance of BKPyV.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 338-347"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access","authors":"Tsung-Yu Ko ,&nbsp;Chih-Cheng Wu ,&nbsp;Mu-Yang Hsieh ,&nbsp;Chung-Wei Yang ,&nbsp;Chi-Hung Cheng ,&nbsp;Chun-Kai Chen ,&nbsp;Hsien-Li Kao","doi":"10.1016/j.kint.2024.10.023","DOIUrl":"10.1016/j.kint.2024.10.023","url":null,"abstract":"<div><div>Dialysis vascular access thrombosis poses a substantial challenge for individuals undergoing hemodialysis. The efficacy and safety of apixaban, a direct oral coagulation factor Xa inhibitor, in preventing recurrent access thrombosis have yet to be explored. Here, a multicenter randomized control study (NCT04489849) enrolled hemodialysis patients to evaluate this who underwent successful endovascular thrombectomy within 48 hours. Participants were assigned to standard care or standard care plus apixaban, 2.5 mg twice daily for three months. The trial design involved open-label administration, with independent adjudication of endpoints. The primary efficacy endpoint was recurrent access thrombosis within three months after thrombectomy. A total of 186 patients with well-balanced baseline characteristics were enrolled, 93 randomized to the apixaban group and 93 to the control group. The apixaban group demonstrated a significantly lower rate of access thrombosis at three months than the control group (24.0% vs. 40.8%; hazard ratio, 0.52 [95% confidence interval 0.31–0.88]), along with a significantly better primary patency failure rate (32.2% vs. 49.5%, 0.57 [0.36–0.91]). Safety outcomes showed comparable death rates and major bleeding incidents but significantly higher incidence of minor bleeding in the apixaban group (22.6% vs. 7.5%). The effect of apixaban did not show interaction in subgroups of different access types, antiplatelet usage, severity of comorbidities, or history of thrombosis. Thus, apixaban effectively reduced the risk of recurrent thrombosis in hemodialysis vascular access post-thrombectomy. Despite a minor increase in bleeding adverse effects, the net clinical benefit favors the use of apixaban in this context.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 2","pages":"Pages 348-358"},"PeriodicalIF":14.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}